F-1/A: NewGenIvf Group Limited Files F-1/A Amendment

NewGenIvf Group Limited files an F-1/A amendment, detailing its ongoing public offering, strategic investments, and financial performance, while addressing Nasdaq listing concerns.

Summary

• NewGenIvf Group Limited has filed an Amendment No. 1 to its Form F-1 Registration Statement, indicating an offering of Class A Ordinary Shares and Pre-Funded Warrants.
• The company is an assisted reproductive services (ARS) provider in Asia-Pacific, with operations in Thailand, Cambodia, and Kyrgyzstan.
• The filing details a history of reverse stock splits to maintain Nasdaq compliance, including recent transfers to the Nasdaq Capital Market.
• Significant strategic initiatives include investments in digital assets and real estate development in the UAE, alongside a new agency agreement for an AI platform.
• The company reported a net income of $9,728,723 for the year ended December 31, 2025, a significant turnaround from a net loss of $(474,101) in 2024.
• However, the company faces substantial risks, including potential going concern issues, competition, and the volatility of its digital asset investments.
• The company has engaged in various debt financing activities, including the issuance of convertible notes, and has a significant amount of outstanding convertible notes.
• The filing also addresses related party transactions, management changes, and extensive risk factors associated with its business operations and the offering.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant financial challenges, ongoing Nasdaq listing concerns, and substantial operational risks, despite some strategic investments.

Positives

• Reported a net income of $9,728,723 for the year ended December 31, 2025, a significant improvement from a net loss in the prior year.
• Acquired MicroSort technology for $750,000 cash and 2,500,000 Class A Ordinary Shares, and Nodexus business for $300,000 cash, recognizing bargain purchase gains of $2.5 million and $19.17 million respectively.
• Regained compliance with Nasdaq's minimum bid price rule after implementing several reverse stock splits.
• Secured a strategic investment agreement for up to a 13% equity interest in PredicXion Group Limited.
• Entered into a significant equity line of credit facility of up to $100,000,000 from White Lion Capital.
• Expanded its service offerings to include fertility referral services, contributing 17.4% of revenue in 2025.
• Has a strong management team with considerable experience in the ARS market.
• Operates in an attractive and growing market for assisted reproductive services in the Asia-Pacific region.

Negatives

• The company may not be able to continue operating as a going concern, with outstanding convertible promissory notes of $9,305,580.75 and significant payment obligations for equity investments.
• Experienced a decrease in revenue from IVF treatment services by 28.11% from 2024 to 2025.
• Gross profit decreased by 47.68% and gross margin fell from 33.6% to 20.2% between 2024 and 2025.
• General and administrative expenses increased significantly by approximately 291.05% in 2025 due to professional fees for real estate projects, increased staff costs, and write-offs.
• The company has no insurance coverage for its operations, exposing it to significant uninsured risks.
• The company's proposed Solana digital assets purchase arrangement with White Lion is novel and subject to extreme volatility and regulatory scrutiny.
• The company has a history of not being able to comply with filing deadlines for SEC reports.
• The company has experienced multiple reverse stock splits, indicating ongoing struggles with Nasdaq listing requirements.

Risks

• The company may not be able to continue operating as a going concern due to significant financial challenges and liquidity shortfalls.
• The competitive fertility market could materially and adversely affect the company's results if it cannot compete effectively.
• The company's limited operating history with its current platform makes it difficult to predict future performance.
• The company's rapid business transformation into a diversified conglomerate involves substantial risks and may not be successful.
• New strategic initiatives may strain the company's management and operational resources.
• The company's real estate development projects are subject to numerous risks that could prevent the realization of projected returns.
• The valuation of acquired assets, such as intellectual property, is complex and subjective and may not be realized.
• The company's marketing efforts depend significantly on positive references from existing clients, and any failure to attract new clients could be detrimental.

Future Outlook

The company plans to offer broad fertility services for fertility tourists, continue investing in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships. However, the company's future outlook is subject to significant risks related to its financial stability, market competition, and the success of its new strategic initiatives.

Management Comments

• We believe that we can help address some of these key challenges of Asia-Pacific fertility industry.
• Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims to become a leader in the Asia Pacific ARS market.
• NewGenIvf intends to provide broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions.

Industry Context

StockSavvy.ai notes that NewGenIvf operates in the growing Asia-Pacific assisted reproductive services (ARS) market, driven by increasing infertility rates and social acceptance of ARS. The company's strategy to offer comprehensive services, leverage technology like MicroSort, and expand through acquisitions aligns with market trends, but faces competition and regulatory complexities.

Comparison to Industry Standards

• The average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication), which is noted as relatively low compared to the US market.
• The company's implantation rate of 70.9% and reduced miscarriage rates by 26.6% are presented as positive clinical outcomes attributed to technologies like PGS.
• The company's revenue from IVF treatments was 100% in 2024 and 82.6% in 2025, indicating a strong reliance on this core service, with fertility referral services emerging in 2025.

Corporate Governance

Legal Proceedings

• Wing Fung Alfred Siu was served a summons for allegedly violating section 17(2) of the Human Reproductive Technology Ordinance (HRTO) in Hong Kong, which prohibits commercial surrogacy arrangements and advertising surrogacy arrangements.
• The company may be subject to claims and allegations relating to intellectual property and other causes.
• The company has no insurance coverage for its operations, exposing it to uninsured risks and potential liabilities.

Related Party Transactions

• Remuneration paid to directors Mr. Siu Wing Fung Alfred and Ms. Fong Hei Yue Tina totaled US$380,000 in 2024 and US$1.76 million in 2025.
• A service agreement was entered into with Harcourt Limited, controlled by Mr. Siu and Ms. Fong, for administrative support fees totaling $230,772 in 2025.
• Consulting services were provided by Mr. Daniel Siu and Mr. Jasper Siu for fund raising activities, receiving $219,045 and $65,000 respectively in 2025.
• Acquired a 2% minority equity interest and made deposits for another 11% equity interest in PredicXion from Mr. Kong Yiu Cheung, a director and shareholder.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of Class A ordinary shares as consideration for acquisitions and potential future equity raises.
• Investors in the current offering face risks associated with the company's financial stability, potential delisting from Nasdaq, and the volatility of its new business ventures.
• Employees may be affected by the company's growth strategy, which includes attracting and retaining qualified personnel, and potential difficulties in hiring and retaining key employees.
• The company's reliance on international clients could be impacted by global travel restrictions, geopolitical events, and currency fluctuations.

Next Steps

• Complete the public offering of Class A Ordinary Shares and Pre-Funded Warrants.
• Continue to invest in upgrading laboratories and facilities.
• Expand service reach through strategic acquisitions and partnerships.
• Develop and market new solutions and services to clients.
• Address ongoing Nasdaq listing requirements and potential delisting concerns.
• Manage financial resources and pursue further capital raises if necessary.

Key Dates

Recommendation

While NewGenIvf operates in a growing market and has shown a significant improvement in net income for 2025, the company faces substantial financial risks, including potential going concern issues, high operating expenses, and a history of Nasdaq compliance problems. The diversification into unrelated sectors like real estate and digital assets adds further complexity and risk. The current offering aims to raise capital, but the 'best efforts' nature and lack of a minimum offering amount create uncertainty. Given the significant risks and the need for further operational improvements and successful execution of its diversified strategy, a 'hold' recommendation is appropriate pending clearer signs of sustained financial health and operational stability.

Keywords

Assisted Reproductive Services, IVF Treatment, Fertility Tourism, MicroSort Technology, Gender Selection, Egg Donation, Surrogacy, Digital Assets